The short version of LC-MS/MS fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-09-03 and is reviewed periodically as new material appears.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C or lower | Desiccated and protected from light |
| Common analytical method | LC-MS/MS | Detects parent drug and metabolites |
| Solubility class | Lipophilic; soluble in organic solvents | Low aqueous solubility |
| Molecular weight | 437.94 g/mol | Calculated from reported formula |
| Synonyms | SR9009; REV-ERB agonist | Code name used in scientific literature |
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
UK academic and end-user community funded by UKRI: UK Metamaterials Network UK Government Rapid Technology Assessment looking at Metamaterials PwC Tech Translated: Metamaterials Centre for Metamaterial Research and Innovation, University of Exeter, UK www.metamaterials.center Institute of Physics, Impact Project Pathway "Commercialising Metamaterials"
=== 2 January === The SAF claimed that RSF brigadier general Ibrahim Delib was killed along with 32 RSF fighters, including a Mauritanian national, after a drone being launched by the group misfired in El Fasher.
Relative bioavailability is one of the measures used to assess bioequivalence (BE) between two drug products. For FDA approval, a generic manufacturer must demonstrate that the 90% confidence interval for the ratio of the mean responses (usually of AUC and the maximum concentration, Cmax) of its product to that of the "brand name drug" is within the limits of 80% to 125%. Where AUC refers to the concentration of the drug in the blood over time t = 0 to t = ∞, Cmax refers to the maximum concentration of the drug in the blood. When Tmax is given, it refers to the time it takes for a drug to reach Cmax. While the mechanisms by which a formulation affects bioavailability and bioequivalence have been extensively studied in drugs, formulation factors that influence bioavailability and bioequivalence in nutritional supplements are largely unknown. As a result, in nutritional sciences, relative bioavailability or bioequivalence is the most common measure of bioavailability, comparing the bioavailability of one formulation of the same dietary ingredient to another.
==== European Union ==== In the European Union, meloxicam is licensed for other anti-inflammatory benefits including relief from both acute and chronic pain in dogs. Meloxicam is also licensed for use in horses, to relieve the pain associated with musculoskeletal disorders. 1998 (January): Meloxicam was authorised for use in cattle throughout the European Union, via a centralised marketing authorisation. 2006: The first generic meloxicam product was approved. 2024 (January): EMA issued an 'Opinion' on a change to this medicine's authorisation concerning the follow-up oral treatment after initial injectable administration in cats. This change remains as an 'Opinion', while the medication continues to be approved as usual.
The stability of nuclei quickly decreases with the increase in atomic number after curium, element 96, whose half-life is over ten thousand times longer than that of any subsequent element. All isotopes with an atomic number above 101 undergo radioactive decay with half-lives of less than 30 hours: this is because of the ever-increasing Coulomb repulsion of protons, so that the strong nuclear force cannot hold the nucleus together against spontaneous fission for long. Calculations suggest that in the absence of other stabilising factors, elements with more than 103 protons should not exist. Researchers in the 1960s suggested that the closed nuclear shells around 114 protons and 184 neutrons should counteract this instability, and create an "island of stability" containing nuclides with half-lives reaching thousands or millions of years. The existence of the island is still unproven, but the existence of the superheavy elements (including nihonium) confirms that the stabilising effect is real, and in general the known superheavy nuclides become longer-lived as they approach the predicted location of the island. All nihonium isotopes are unstable and radioactive; the heavier nihonium isotopes are more stable than the lighter ones, as they are closer to the centre of the island. The most stable known nihonium isotope, 286Nh, is also the heaviest; it has a half-life of 8 seconds. The isotope 285Nh, as well as the unconfirmed 287Nh and 290Nh, have also been reported to have half-lives of over a second.
Sources: en.wikipedia.org
== Contraindications == Methylergometrine is contraindicated in patients with hypertension and pre-eclampsia. It is also contraindicated in HIV positive patients taking protease inhibitors, delavirdine, and efavirenz (which is also an agonist at the 5-HT2A–mGlu2 receptor protomer and increases the chances of a patient experiencing hallucinations during methylergometrine therapy).
== Adverse effects == Cefodizime has been shown to be generally well tolerated in drug trials and its adverse effects are mainly gastrointestinal or dermatological. Gastrointestinal adverse effects were observed in 2.4% of patients during clinical trials and included: diarrhea, nausea, vomiting, and elevated transaminases. Allergic symptoms were observed in 1.1% of patients and include: exanthema, urticaria, and pruritus. Other adverse effects observed include local site reactions, pain at site of injection, and phlebitis.
Ketone bodies can be used as fuels, yielding 22 ATP and 2 GTP molecules per acetoacetate molecule when oxidized in the mitochondria. Ketone bodies are transported from the liver to other tissues, where acetoacetate and beta-hydroxybutyrate can be reconverted to acetyl-CoA to produce reducing equivalents (NADH and FADH2), via the citric acid cycle. Ketone bodies cannot be used as fuel by the liver, because the liver lacks the enzyme β-ketoacyl-CoA transferase, also called thiolase. Acetoacetate in low concentrations is taken up by the liver and undergoes detoxification through the methylglyoxal pathway which ends with lactate. Acetoacetate in high concentrations is absorbed by cells other than those in the liver and enters a different pathway via 1,2-propanediol. Though the pathway follows a different series of steps requiring ATP, 1,2-propanediol can be turned into pyruvate.
Ion-exchange membranes are traditionally used in electrodialysis or diffusion dialysis by means of an electrical potential or concentration gradient, respectively, to selectively transport cationic and anionic species. When applied in an electrodialysis desalination process, anion- and cation-exchange membranes are typically arranged in an alternating pattern between two electrodes (an anode and a cathode) within the electrodialysis stack. A galvanic potential is supplied as a voltage generated at the electrodes. A typical industrial electrodialysis stack consists of two chambers: a product-water chamber and a concentrate-reject chamber. During stack operation, salts are transferred from the product to the concentrate. As a result, the reject stream is concentrated up while the product stream is desalted. Exemplary applications of ion-exchange membranes utilized in electrodialysis and EDR include seawater desalination, industrial wastewater treatment of highly scaling waters, food and beverage production, and other industrial wastewaters. Proton-exchange membrane
Sources: en.wikipedia.org
Americium-241 (241Am, Am-241) is an isotope of americium. Like all isotopes of americium, it is radioactive, with a half-life of 432.6 years. 241Am is the most common isotope of americium as well as the most prevalent americium isotope in radioactive waste. It is used in ionization-type smoke detectors and is a potential fuel for long-lifetime radioisotope thermoelectric generators (RTGs). Its common parent nuclides are 241Pu (by beta decay), 241Cm (by electron capture), and 245Bk (by alpha decay). 241Am is fissile, with the critical mass of a bare sphere of 57.6–75.6 kilograms (127.0–166.7 lb) (diameter of 19–21 centimetres (7.5–8.3 in)). Americium-241 has a specific activity of 3.43 Ci/g (126.91 GBq/g). It is commonly found in the form of americium-241 dioxide (241AmO2). The presence of 241Am in plutonium is determined by the original concentration of plutonium-241 (which decays to it) and its age. Older samples of plutonium containing 241Pu build up 241Am and may require chemical removable of americium-241 (e.g., during reworking of plutonium's pits).
Lobeglitazone (trade name Duvie, Chong Kun Dang) is an antidiabetic drug in the thiazolidinedione class of drugs. As an agonist for both PPARα and PPARγ, it works as an insulin sensitizer by binding to the PPAR receptors in fat cells and making the cells more responsive to insulin.
=== Since 2014 === In early 2014, Marcel H. Van Herpen, director of the Cicero Foundation, published the book Putin's Wars: The Rise of Russia's New Imperialism that offered the first systematic analysis of the war in the wider historical context. Van Herpen suggested that although the official Russian narrative (that the war started with a Georgian "surprise" attack on Tskhinvali) became widely accepted, this was not true since the war's history actually began in 2000 (although Russia had planned to annex Abkhazia already in the 1990s), and 7–12 August 2008 was the third phase of the war. Illegal entry of the troops from Russia into South Ossetia before the Georgian military operation began on 7 August, was a casus belli. Because of the Russian propaganda, the victim (Georgia) became the aggressor. Van Herpen finished writing the book in late 2013, and predicted "if Ukraine were to opt for deeper integration into the European Union, a Georgia scenario could not be excluded, in which the Kremlin could provoke riots in Eastern Ukraine or the Crimea, where many Russian passport holders live". In April 2014, Jeffrey Mankoff argued that Russia and South Ossetia provoked the Georgian response. Mankoff also noted that while Russia used the justification of the defense of minorities in Georgia for military intervention, Russia never intervened in Central Asia to protect ethnic Russians there.
In practice, Vicryl comes braided, dyed or undyed with the following decay schedule: 75% at two weeks, 50% at three weeks, and 25% at four weeks (i.e., the sutures retain that proportion of tensile strength at those dates).
From a clinical perspective, two significant school of thought exists for psychiatric conditions associated with cannabis (or cannabinoids) use: transient, non-persistent psychotic reactions, and longer-lasting, persistent disorders that resemble schizophrenia. The former is formally known as acute cannabis-associated psychotic symptoms (CAPS) or cannabis-induced psychotic disorder (CIPD). At an epidemiological level, a dose–response relationship exists between cannabis use and increased risk of psychosis and earlier onset of psychosis. Although the epidemiological association is robust, evidence to prove a causal relationship is lacking. Cannabis may also increase the risk of depression, but insufficient research has been performed to draw a conclusion. A 2014 meta-analysis of longitudinal studies found that cannabis use was associated with a modestly increased risk of developing depressive disorders, particularly among heavy users, although the causal relationship remains uncertain and further research is needed. Cannabis use is associated with increased risk of anxiety disorders, although causality has not been established. A 2025 systematic review and meta-analysis involving more than half a million participants aged 15–30 reported that cannabis use was associated with higher odds of depression (51% higher), anxiety (58%), suicidal ideation (65%), and suicide attempt (87%). A review in 2019 found that research was insufficient to determine the safety and efficacy of using cannabis to treat schizophrenia, psychosis, or other mental disorders.
Sources: en.wikipedia.org
Liquid chromatography-tandem mass spectrometry is a common approach. It can detect the parent compound and its metabolites in biological matrices.
Research samples are typically kept frozen, desiccated, and protected from light. Stock solutions are often aliquoted to reduce freeze-thaw cycles.
High-performance liquid chromatography and nuclear magnetic resonance are standard for purity and identity. Mass spectrometry confirms molecular weight.
Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.